✦ LIBER ✦

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

✍ Scribed by Bendell, J. C.; Rodon, J.; Burris, H. A.; de Jonge, M.; Verweij, J.; Birle, D.; Demanse, D.; De Buck, S. S.; Ru, Q. C.; Peters, M.

Book ID: 111952283
Publisher: American Society of Clinical Oncology
Year: 2012
Tongue: English
Weight: 196 KB
Volume: 30
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2011.36.1360

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I dose-escalation and -expansion s

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

✍ Rodon, Jordi; Braña, Irene; Siu, Lillian L; Jonge, Maja J; Homji, Natasha; Mills 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 925 KB

193 Phase I Safety Experience with the O

193 Phase I Safety Experience with the Oral Pan-class I PI3K Inhibitor BKM120 in Patients with Metastatic Breast Cancer (mBC)

✍ C. Saura; H. Burris; C.L. Arteaga; I. Mayer; C. Germa; N. Fretault; D. Sternberg 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 63 KB

366 Phase I Dose-escalation Study of the

366 Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors

✍ Ahnert, J. Rodon; Burris, H.A.; Schellens, J.H.M.; Schuler, M.; Goodman, O.; Bri 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Phase I dose-escalation study of the HSP

Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors

✍ Toshihiko Doi,Yusuke Onozawa,Nozomu Fuse… 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 733 KB

Phase I Dose-Escalation and Pharmacokine

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

✍ Demetri, G. D.; Lo Russo, P.; MacPherson, I. R.J.; Wang, D.; Morgan, J. A.; Brun 📂 Article 📅 2009 🏛 American Association for Cancer Research 🌐 English ⚖ 238 KB

1243 Phase I dose-escalation study of co

1243 Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumors

✍ H. Kaneda; I. Okamoto; T. Satoh; T. Arao; K. Nishio; A. Sarashina; K. Konishi; P 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 53 KB